Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Q32 Bio Inc. (QTTB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | $1.2M | $3.2M | $34.0M | $2.7M | $1.7M | $5.3M | — |
| Research & development | $19.2M | $48.1M | $31.7M | $98.4M | $93.1M | $100.4M | $89.4M | $47.9M | $21.4M |
| Operating expenses | $36.8M | $66.1M | $41.6M | $136.5M | $129.9M | $133.0M | $111.6M | $65.2M | $29.7M |
| Operating income | $16.9M | −$66.1M | −$48.3M | −$133.3M | −$95.9M | −$130.3M | −$109.9M | −$59.9M | −$29.7M |
| Net income | $29.8M | −$47.7M | −$53.7M | −$5.0M | −$95.8M | −$128.7M | −$103.9M | −$55.6M | −$30.0M |
| Basic EPSper diluted share | $2.42 | -$5.12 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
| Diluted EPSper diluted share | $2.42 | -$6.58 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 28, 2026Form 4 | Xu DiyongDirector,TenPercentOwner | BuyCommon Stock · indirect | 625.0K | $8.00 | $5.00M | 625.0K |
| May 28, 2026Form 4 | Xu DiyongDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.25M | $8.00 | $10.00M | 3.50M |
| May 28, 2026Form 4 | OrbiMed Capital GP VII LLC +2Director,TenPercentOwner | BuyCommon Stock · indirect | 625.0K | $8.00 | $5.00M | 625.0K |
| May 28, 2026Form 4 | OrbiMed Capital GP VII LLC +2Director,TenPercentOwner | BuyCommon Stock · indirect | 1.25M | $8.00 | $10.00M | 3.50M |
| Feb 25, 2026Form 4 | Kalowski LeeCFO and President | SellCommon Stock | 4.0K | $4.51 | $18.0K | 35.9K |